Second and Third Kidney Transplantation in the Catholic Organ Transplantation Center.
- Author:
Hyo Sin JEON
1
;
Sun Cheol PARK
;
Bum Soon CHOI
;
Chul Woo YANG
;
In Sung MOON
;
Yong Bok KOH
Author Information
1. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. sun60278@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Kidney retransplantation
- MeSH:
Cadaver;
Cause of Death;
Cyclosporine;
Female;
Graft Survival;
Humans;
Immunosuppression;
Kidney Transplantation*;
Kidney*;
Living Donors;
Mortality;
Organ Transplantation*;
Quality of Life;
Renal Insufficiency;
Retrospective Studies;
Tissue Donors;
Transplants*
- From:The Journal of the Korean Society for Transplantation
2006;20(1):69-72
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was designed to review the results of 2nd and 3rd kidney transplantation at our center. METHODS: Total 1,500 patients who had undergone kidney transplantation from 1968 to Aug 2005 at the Catholic Medical Center were retrospectively analyzed. The graft and patient survival were determined using Kaplan-Meier actuarial survival curves, compared with those of first transplant and assessed for significance using the log rank test. RESULTS: The patient of 2nd transplantation was 77 cases (male 55, female 22, mean age: 48.9+/-2.4 years) and 3rd transplantation was 5 patients (male 4, female 1, mean age 46.8+/-6.0 years). The 82 kidneys included from living donors in 67 patients and from cadaveric donors in 15 patients. The most common cause of renal failure of retransplanted kidney was chronic GN (2nd: 62 cases (80.5%), 3rd: 5 cases (100%)). The immunosuppressive regimen was mainly based on cyclosporine (2nd: 61 cases (79.2%), 3rd: 3 cases (60%)). The mean duration of the second transplantation from the first was 89.0 months and the third transplantation from the second was 32.7 months. There were 16 cases of death patients and the main cause of death was infection and cardiovascular events. The graft survival of 2nd & 3rd transplantation in 1 year were over 80%. CONCLUSION: Renal retransplantation is safe, effective, and the treatment of choice in patients with failed previous kidney transplantation for patient's quality of life and not associated with increased mortality retransplantation. The results of graft survival for retransplantation seem to be excellent for primary transplantation under cyclosporine or tacrolimus-based immunosuppression. The use of the potent and appropriate immunosuppression and surgical technique for retransplantation could help to improve better results.
